Protein liquid phase chip technology --- biomarker detection.

liquid-phase chip technology was developed in the late 1990s and is known as the" era chip technology. Liquid-phase chip technology combines flow detection technology with chip technology >organism", on the one hand greatly extending the flow detection platform, replacing cells with microspheres as reaction vectors, this fairly open reaction system can detect proteins, nucleic acids and other biomolecules, not only from the cell level to the molecular level, its The range of detections has also been expanded like never before, and on the other hand, it has led to a major breakthrough in chip technology: while maintaining high-volume detection, changing the reaction system from liquid-solid to a complete liquid reaction system close to the internal environment of the biological system is particularly critical to ensuring trueinteractions based on the correct advanced structure. In less than a decade, hundreds of testing platforms based on this technology (xMAP:flexible Multi-Analyte Profiling) have been used in protein,immunology and other fields, clinical diagnosis" > reagents have also developed rapidly, autoimmune diagnostic reagents and other fields have passed the FDA certification.

Merck Millibo and Luminx's latest generation of magnetic bead multiple detection system, MAGPIX, in 2010, features a revolutionary optical system and flow system that makes the new MAGPIX more compact, with a new LED-inspired light source and high-resolution CCD imaging technology in light path design, combined with powerful xPON ENT software, can fully achieve a single sample of up to 50 kinds of analyte multi-detection, Merck Millibo for MAGPIX products specifically launched up to 25 kinds of Miliplex kits can be applied on MAGPIX, covering metabolic diseases, inflammation, cardiovascular disease, neuroscience, signal transductivity, tumor markers and other aspects, Merck Millibo is currently the world's most comprehensive magnetic bead immunoassiotic test kit provider.

biomarker first appeared in the National Research Council's (NRC) red book, Federal Risk Assessment, published in 1983. It refers to the ef indicator that can mark systems, organs, , changes in the structure or function of cells and subcellulars, or possible changes, and has > a very wide range of uses. For example, in the field of medicine, biomarkers can be used for disease diagnosis (e.g., prostate specificity antigens PSA can be used for prostate cancer diagnosis), to determine disease stages (e.g., stages of malignant tumors), or to evaluate the safety and effectiveness of new drugs or therapies in target populations.

For disease research, biomarkers generally refer to a general physiological or pathological or therapeutic process of a characteristic biochemical indicator that can be objectively measured and evaluated, through which the body's current biological process process can be known. Examining a disease-specific biomarker may help in the identification, early diagnosis and prevention of the disease, and monitoring during treatment. The search for and discovery of valuable biomarkers has become an important hot spot in current research. Liquid-phase chip technology is a tool ideal for biomarker exploration and research, with samples of up to 25 μl required to detect up to hundreds of indicators simultaneously.

one. Detection items

currently offers the following liquid-phase chip detection experiment services:

1. Users purchase their own Milliplex bead kits or magnetic bead kits compatible with MAGPIX machines and provide samples, with samples tested by kit and test data provided by the center.

2. The user provides samples, the center provides all-inclusive services according to the available bead kit (the user does not need to provide the kit), the center provides sample testing services and provides testing data. The following image shows the types of magnetic bead kits that can be carried out by the Center, the details of which need to be confirmed with the Center in advance.

II, charge